


Breakout group 2

Which new paradigms (clinical and scientific) should be further investigated by IDEA?

Moderator: Ian Kimber

Breakout group 2 - Key conclusions



- Given the time, we selected not to look at the potency aspects of elicitation but we recognize this is important and should be included in future discussions.
- We all agree that for any of this work we need a reference chemical database that can be used to calibrate anything that gets developed on this area.
- Consideration of all available human and EC3 data.
- We looked at protein binding and formation already in some tests, but it might need to be looked at in more detail (strength of reaction)
- Danger signals we look at various ways to inform this, maybe also looking at dendritic cell biology and consider an approach that combines danger signals and dendritic cells biological responses.
- We might need a tiered approach where we have (an) assay(s) for hazard followed by (an) assay(s) for potency.

Thank you for your attention

